Pritesh Shah Biography and Net Worth

Insider of NovoCure

Pritesh Shah joined Novocure in November 2012 and serves as Chief Commercial Officer. Prior to joining Novocure, Mr. Shah had extensive experiences in leading oncology commercial and medical affairs functions at Roche, Genentech, Bristol-Myers Squibb, OSI Oncology and AVEO Oncology. He holds a Doctor of Pharmacy from the University of Maryland and a master’s degree in Strategic Communication and Leadership from Seton Hall University.

What is Pritesh Shah's net worth?: The estimated net worth of Pritesh Shah is at least $2.36 million as of November 7th, 2023. Mr. Shah owns 124,511 shares of NovoCure stock worth more than $2,360,853 as of March 27th. This net worth estimate does not reflect any other assets that Mr. Shah may own. Learn More about Pritesh Shah's net worth.
How do I contact Pritesh Shah?: The corporate mailing address for Mr. Shah and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at investorinfo@novocure.com. Learn More on Pritesh Shah's contact information.
Has Pritesh Shah been buying or selling shares of NovoCure?: Pritesh Shah has not been actively trading shares of NovoCure within the last three months. Most recently, Pritesh Shah sold 382 shares of the business's stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $12.65, for a transaction totalling $4,832.30. Following the completion of the sale, the insider now directly owns 124,511 shares of the company's stock, valued at $1,575,064.15. Learn More on Pritesh Shah's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Mukund Paravasthu (COO), Michael Puri (Insider), Pritesh Shah (Insider), William Vernon (Director), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 5 times. They sold a total of 3,220 shares worth more than $61,749.10. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

Pritesh Shah Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/7/2023	Sell	382	$12.65	$4,832.30	124,511
9/1/2023	Sell	273	$21.82	$5,956.86	124,893
3/9/2022	Sell	3,669	$71.19	$261,196.11
3/7/2022	Sell	5,294	$69.55	$368,197.70
8/4/2021	Sell	2,063	$148.71	$306,788.73	74,169
6/10/2021	Sell	23,540	$215.00	$5,061,100.00	77,732
5/5/2021	Sell	1,290	$199.67	$257,574.30	101,272
9/9/2020	Sell	28,321	$85.41	$2,418,896.61	71,165
5/4/2020	Sell	1,184	$60.08	$71,134.72	103,026
2/25/2020	Sell	5,067	$81.16	$411,237.72	75,653
8/1/2019	Sell	7,020	$83.00	$582,660.00	82,091
7/26/2019	Sell	12,500	$77.94	$974,250.00	89,476
7/18/2019	Sell	7,500	$70.00	$525,000.00	84,476
6/27/2019	Sell	11,175	$60.30	$673,852.50	65,037
6/19/2019	Sell	12,500	$60.00	$750,000.00	88,712
6/10/2019	Sell	1,130	$55.05	$62,206.50	76,272
5/2/2019	Sell	1,204	$43.80	$52,735.20
2/28/2019	Sell	1,558	$53.68	$83,633.44	26,797
1/16/2019	Sell	25,000	$45.00	$1,125,000.00	29,587
1/11/2019	Sell	26,251	$42.00	$1,102,542.00	25,838
1/9/2019	Sell	8,988	$40.00	$359,520.00	26,075
12/12/2018	Sell	38,781	$36.00	$1,396,116.00	39,619

See Full Table

Pritesh Shah Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $18.97

$18.31

$19.06

50 Day Range

MA: $21.87

$18.19

$27.02

2 Week Range

Now: $18.97

$11.70

$34.13

Volume

490,446 shs

Average Volume

1,191,815 shs

Market Capitalization

$2.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63